vWD

Von Willebrand's Disease is the most prevalent inherited bleeding disorder in dogs, caused by a deficiency or dysfunction of Von Willebrand factor (vWF), a glycoprotein essential for normal platelet adhesion and clot formation. The condition is named after Finnish physician Erik von Willebrand, who first described the disorder in humans in 1926. In dogs, vWD was first characterized in the 1970s, and since then it has been identified in over 50 breeds as well as mixed-breed dogs. The disease affects the primary hemostatic process, meaning that dogs with vWD have difficulty forming the initial platelet plug needed to stop bleeding from damaged blood vessels.

Von Willebrand factor is produced by vascular endothelial cells and megakaryocytes. It serves two critical functions in hemostasis: it mediates platelet adhesion to exposed subendothelial collagen at sites of vascular injury, and it acts as a carrier protein for clotting Factor VIII, protecting it from premature degradation in the bloodstream. When vWF is deficient or structurally abnormal, platelets cannot adhere properly to damaged vessel walls, leading to prolonged bleeding times and excessive hemorrhage even from minor wounds or surgical procedures.

The severity of vWD varies widely among affected dogs. Some dogs carry the genetic mutation but show no clinical signs throughout their lives, while others experience life-threatening hemorrhagic episodes. This variability depends on the type of vWD, the degree of vWF deficiency, and individual physiological factors. Environmental stressors, concurrent illnesses, certain medications, and hormonal fluctuations can all influence the clinical expression of the disease in genetically affected animals.

Understanding vWD is particularly important for breeders, veterinarians, and dog owners because many affected dogs appear completely healthy until they undergo surgery, sustain an injury, or experience another hemostatic challenge. The widespread availability of genetic testing has significantly improved the ability to identify carriers and affected dogs before clinical signs emerge, allowing for informed breeding decisions and appropriate surgical precautions.

Von Willebrand's Disease in dogs is classified into three distinct types based on the nature of the vWF abnormality, each with different clinical implications and breed predispositions. Type 1 vWD is the most common form and is characterized by a quantitative deficiency of structurally normal Von Willebrand factor. Dogs with Type 1 vWD produce vWF that functions properly but in insufficient amounts. This form is typically associated with mild to moderate bleeding tendencies and is most frequently seen in Doberman Pinschers, where the carrier rate has been reported to exceed 50 percent in some populations. Other commonly affected breeds include German Shepherds, Standard Poodles, Shetland Sheepdogs, Golden Retrievers, Miniature Schnauzers, and Pembroke Welsh Corgis.

Type 2 vWD involves a qualitative defect in which the dog produces Von Willebrand factor that is structurally and functionally abnormal. Specifically, the larger multimeric forms of vWF, which are the most hemostatically active, are disproportionately reduced or absent. This results in a more severe bleeding tendency compared to most Type 1 cases, despite the fact that total vWF antigen levels may appear only moderately reduced. Type 2 vWD is most commonly identified in German Wirehaired Pointers and German Shorthaired Pointers, and the inheritance pattern in these breeds has been well-characterized through extensive genetic studies.

Type 3 vWD is the most severe form of the disease and is characterized by a virtually complete absence of Von Willebrand factor in the blood. Dogs with Type 3 vWD experience severe, often life-threatening hemorrhagic episodes that can occur spontaneously or in response to minimal trauma. This form follows an autosomal recessive inheritance pattern and has been documented in Scottish Terriers, Chesapeake Bay Retrievers, Shetland Sheepdogs, and Dutch Kooikerhondjes. Because vWF also serves as a carrier for Factor VIII, dogs with Type 3 vWD may have concurrent reductions in Factor VIII activity, further compounding the bleeding diathesis.

The distinction between types is clinically significant because it determines the expected severity of bleeding episodes, guides treatment decisions, and informs prognosis. Genetic testing can now identify the specific mutation responsible for each type in many breeds, allowing for definitive diagnosis rather than reliance on vWF antigen levels alone, which can fluctuate due to stress, hormonal status, and other factors.

Von Willebrand's Disease is caused by mutations in the VWF gene, which encodes the Von Willebrand factor protein. The VWF gene is located on an autosomal chromosome, meaning that vWD is not sex-linked and affects males and females with equal frequency. The specific genetic mutations responsible for vWD vary between types and breeds. In Doberman Pinschers with Type 1 vWD, a splice site mutation in the VWF gene has been identified that leads to reduced production of the protein. In Scottish Terriers with Type 3 vWD, a different mutation causes a premature stop codon, resulting in a severely truncated and nonfunctional protein.

The inheritance patterns differ among the types of vWD. Type 1 vWD in most breeds is inherited as an autosomal trait with incomplete dominance, meaning that dogs with one copy of the mutant allele (heterozygous carriers) typically have intermediate levels of vWF and may or may not show clinical signs. Dogs with two copies of the mutant allele (homozygous affected) generally have lower vWF levels and a greater likelihood of clinical bleeding. However, the relationship between genotype and phenotype in Type 1 vWD is not always straightforward, as some homozygous dogs remain clinically silent while some heterozygous carriers experience significant bleeding.

Types 2 and 3 vWD follow a more predictable autosomal recessive inheritance pattern. In these forms, only dogs that inherit two copies of the mutant allele develop clinical disease, while heterozygous carriers are generally asymptomatic. This recessive pattern means that two clinically normal carrier parents can produce affected offspring, which underscores the importance of genetic testing in breeding programs. For breeds with known vWD mutations, DNA-based tests provide definitive genotyping that is unaffected by age, stress, concurrent disease, or sample handling.

Environmental and physiological factors can modulate the expression of vWD even in genetically affected dogs. Hypothyroidism, for example, has been associated with decreased vWF levels and may exacerbate bleeding tendencies in dogs with underlying vWD. Stress, pregnancy, and certain medications including nonsteroidal anti-inflammatory drugs and some antibiotics can also influence vWF levels and platelet function, potentially unmasking or worsening the bleeding phenotype in predisposed animals.

The clinical signs of Von Willebrand's Disease in dogs are primarily related to impaired primary hemostasis, resulting in mucosal and surface bleeding rather than the deep tissue or joint hemorrhages more characteristic of clotting factor deficiencies such as hemophilia. The most commonly observed symptom is prolonged or excessive bleeding from minor wounds, surgical sites, or during routine procedures such as nail trimming and ear cropping. Many owners first become aware of the condition when their dog experiences unexpectedly heavy bleeding during a spay, neuter, or dental procedure.

Spontaneous bleeding from mucosal surfaces is a hallmark of vWD. This may manifest as recurrent epistaxis (nosebleeds), bleeding from the gums, hematuria (blood in the urine), melena or hematochezia (blood in the stool), and prolonged or excessive bleeding during estrus cycles in intact females. Some dogs develop petechiae or ecchymoses, which are small pinpoint or larger areas of bruising in the skin or mucous membranes, although these findings are more variable and may not be prominent in milder cases.

The severity and frequency of symptoms correlate broadly with the type and degree of vWF deficiency. Dogs with Type 1 vWD and moderate vWF levels may go their entire lives without a clinically significant bleeding episode, especially if they never undergo surgery or sustain a significant injury. In contrast, dogs with Type 3 vWD may experience spontaneous hemorrhage into the gastrointestinal tract, urinary tract, or body cavities, which can lead to acute anemia, weakness, collapse, and potentially death if not treated promptly.

It is important to recognize that the signs of vWD can be episodic and unpredictable. A dog that has previously tolerated minor procedures without excessive bleeding may still experience a severe hemorrhagic event under different circumstances, particularly if concurrent factors such as infection, inflammation, medication use, or hormonal changes are present. This intermittent nature of clinical signs can delay diagnosis and may lead to the condition being overlooked until a crisis occurs.

Owners should be vigilant for subtle signs that may indicate a bleeding tendency, such as blood-tinged saliva, prolonged bleeding from deciduous tooth loss in puppies, unexplained bruising, or dark tarry stools. Any dog with a history of unexplained or disproportionate bleeding should be evaluated for vWD, regardless of breed.

Diagnosis of Von Willebrand's Disease involves a combination of clinical history, screening tests, specific vWF assays, and genetic testing. The initial evaluation typically begins with a thorough history focusing on any episodes of prolonged or excessive bleeding, as well as a review of the dog's breed, family history, and any medications that could affect hemostasis. Standard coagulation tests such as prothrombin time (PT) and activated partial thromboplastin time (aPTT) are usually normal in dogs with vWD, because these tests evaluate the secondary coagulation cascade rather than primary hemostasis.

The buccal mucosal bleeding time (BMBT) is a practical screening test that evaluates primary hemostasis in vivo. A standardized incision is made on the inner surface of the upper lip using a spring-loaded device, and the time required for bleeding to cease is measured. Dogs with significant vWF deficiency typically have prolonged BMBT results, generally exceeding four to five minutes compared to the normal range of two to four minutes. However, BMBT results can be influenced by technique, patient cooperation, and concurrent conditions, so this test is best used as a screening tool rather than a definitive diagnostic measure.

The Von Willebrand factor antigen (vWF:Ag) assay is the standard diagnostic test for quantifying the amount of vWF in the plasma. This test uses enzyme-linked immunosorbent assay (ELISA) methodology to measure the total concentration of vWF protein. Results are reported as a percentage of normal pooled plasma, with values below 50 percent generally considered consistent with vWD. Values below 35 percent are associated with a higher risk of clinical bleeding, while values below 15 percent are typically seen in dogs with moderate to severe disease. It is important to note that vWF:Ag levels can fluctuate significantly due to stress, exercise, pregnancy, age, and concurrent illness, so borderline results should be interpreted with caution and may warrant repeat testing.

Genetic DNA testing has become the gold standard for definitive diagnosis in breeds where the causative mutations have been identified. DNA tests are available for Type 1 vWD in Doberman Pinschers, Bernese Mountain Dogs, Manchester Terriers, Pembroke Welsh Corgis, Poodles, and several other breeds. Type 2 testing is available for German Wirehaired Pointers and German Shorthaired Pointers, and Type 3 testing is available for Scottish Terriers, Shetland Sheepdogs, and Dutch Kooikerhondjes. These tests provide unambiguous results that classify dogs as clear, carrier, or affected, independent of environmental variables.

Multimer analysis is an advanced laboratory test that evaluates the distribution of vWF multimeric forms and is particularly useful in distinguishing Type 2 vWD from other types. This test is performed at specialized reference laboratories and is not routinely needed for clinical diagnosis in most cases.

There is no cure for Von Willebrand's Disease, as it is a genetic condition, but effective treatment strategies exist to manage bleeding episodes and minimize hemorrhagic risks. The cornerstone of acute treatment for significant bleeding in dogs with vWD is transfusion therapy. Fresh whole blood or cryoprecipitate are the products of choice because they contain functional Von Willebrand factor. Cryoprecipitate is the preferred product when available, as it provides a concentrated source of vWF, Factor VIII, and fibrinogen in a smaller volume, reducing the risk of volume overload and transfusion reactions.

Fresh frozen plasma (FFP) can also be used to supply vWF, although it provides a lower concentration of the factor compared to cryoprecipitate and requires larger volumes to achieve therapeutic levels. Stored or previously frozen plasma that has been thawed and refrozen does not contain adequate levels of functional vWF and should not be relied upon for treatment of active hemorrhage in dogs with vWD. The decision to transfuse is based on the severity of bleeding, the patient's clinical status, and hemodynamic stability.

Desmopressin acetate (DDAVP) is a synthetic analogue of antidiuretic hormone that can temporarily increase vWF levels by stimulating release of stored vWF from vascular endothelial cells. DDAVP is most effective in dogs with Type 1 vWD, where it may transiently raise vWF levels by two to five times baseline. It is typically administered intravenously or subcutaneously at a dose of one microgram per kilogram approximately 30 minutes before a planned surgical procedure. The effect is short-lived, lasting approximately two to four hours, and repeated doses within a short period produce diminished responses due to depletion of endothelial vWF stores. DDAVP is generally ineffective in Type 2 and Type 3 vWD.

Local hemostatic measures are important adjuncts in managing bleeding in dogs with vWD. Direct pressure, topical hemostatic agents such as gelatin sponges or oxidized cellulose, tissue adhesives, and careful electrocautery can help control surgical or wound-related bleeding. Avoiding medications that impair platelet function, including aspirin, other nonsteroidal anti-inflammatory drugs, and certain antibiotics, is critical in all dogs with known or suspected vWD.

In emergency situations where a dog with vWD presents with acute, life-threatening hemorrhage, rapid stabilization with intravenous fluid therapy, blood product transfusion, and identification and control of the bleeding source are priorities. Close monitoring of packed cell volume, total protein, and blood pressure is essential during and after treatment.

Surgical procedures represent one of the highest-risk situations for dogs with Von Willebrand's Disease, and careful preoperative planning is essential to minimize hemorrhagic complications. All dogs belonging to breeds with a known predisposition to vWD should be tested before any elective surgical procedure, including routine spays, neuters, and dental cleanings. Ideally, both vWF antigen levels and genetic testing should be performed well in advance of the planned procedure to allow adequate time for results and preparation.

Preoperative preparation for dogs with confirmed vWD includes ensuring the availability of appropriate blood products, specifically cryoprecipitate or fresh whole blood, at the surgical facility before the procedure begins. For dogs with Type 1 vWD and moderate vWF levels, administration of DDAVP 30 minutes before the induction of anesthesia can provide a temporary increase in circulating vWF. Blood typing and crossmatching should be completed in advance in case transfusion becomes necessary during or after surgery.

Surgical technique in dogs with vWD should emphasize meticulous hemostasis throughout the procedure. Surgeons should minimize tissue trauma, ligate or cauterize all visible blood vessels, and use topical hemostatic agents liberally. Blunt dissection should be avoided in favor of sharp dissection with immediate hemostasis. The surgical team should be prepared for longer procedure times and should have additional blood products readily available. Minimally invasive techniques, when appropriate for the procedure, may reduce the overall hemorrhagic risk.

Postoperative monitoring is critical and should include frequent assessment of the surgical site for signs of continued or delayed bleeding, serial measurement of packed cell volume and total protein, and close observation for signs of internal hemorrhage such as abdominal distension, pallor, tachycardia, or hypotension. Activity restriction during the recovery period is more important in dogs with vWD than in unaffected dogs, as even moderate activity can disrupt fragile clot formation at the surgical site.

Elective surgical procedures in dogs with severe vWD (Type 3 or Type 1 with very low vWF levels) should be carefully weighed against the hemorrhagic risk. When surgery is necessary, it should be performed at a facility with access to blood banking services and emergency transfusion capabilities. Communication between the primary care veterinarian, surgeon, and anesthesiologist regarding the patient's vWD status and management plan is essential for a safe outcome.

Von Willebrand's Disease has been documented in over 50 dog breeds, but certain breeds carry significantly higher prevalence rates due to founder effects and historical breeding practices. The Doberman Pinscher is by far the most commonly affected breed for Type 1 vWD, with studies reporting carrier rates as high as 50 to 70 percent in some populations. The high prevalence in Dobermans is believed to result from the relatively small founding population of the breed and subsequent inbreeding. Fortunately, widespread genetic testing in Dobermans has allowed breeders to make informed mating decisions, and the prevalence of clinically affected dogs has been gradually declining in well-managed breeding programs.

German Wirehaired Pointers and German Shorthaired Pointers are the breeds most commonly affected by Type 2 vWD. The prevalence of the causative mutation in these breeds varies by geographic region and breeding population, but it remains a significant concern. Because Type 2 vWD involves a qualitative defect with disproportionate loss of high-molecular-weight multimers, affected dogs in these breeds tend to have a more severe bleeding phenotype compared to typical Type 1 cases.

Type 3 vWD, the most severe form, has been well-characterized in Scottish Terriers, Chesapeake Bay Retrievers, Shetland Sheepdogs, and Dutch Kooikerhondjes. In Scottish Terriers, the carrier rate has been estimated at approximately 15 to 20 percent in some populations. Because Type 3 is autosomal recessive, affected puppies are only produced when both parents are carriers, which highlights the critical importance of genetic testing before breeding in these at-risk breeds.

Other breeds with notable prevalence of vWD include Golden Retrievers, Standard and Miniature Poodles, Bernese Mountain Dogs, Pembroke Welsh Corgis, Manchester Terriers, Papillons, and Miniature Schnauzers. Mixed-breed dogs can also be affected, particularly those with significant genetic contribution from predisposed breeds. The availability of breed-specific DNA tests has made it increasingly feasible and affordable to screen all breeding animals in at-risk breeds, and many breed clubs now recommend or require vWD testing as part of their health certification protocols.

It is worth noting that the prevalence data for vWD can vary significantly between studies depending on the population sampled, the testing methodology used, and the geographic region. Breeders and veterinarians should consult current breed-specific health databases and testing laboratories for the most up-to-date prevalence information.

Managing daily life with a dog diagnosed with Von Willebrand's Disease requires awareness, preparation, and some modifications to routine care, but most dogs with mild to moderate forms of the disease can lead full, active, and happy lives. The foundation of long-term management is knowing the dog's specific type and severity of vWD, having this information prominently noted in the veterinary medical record, and ensuring that all veterinary staff who interact with the dog are aware of the diagnosis.

Environmental modifications should focus on reducing the risk of traumatic injuries that could provoke bleeding episodes. This does not mean the dog needs to live in a padded room, but common-sense precautions are appropriate. Avoiding rough play with other dogs or in environments with sharp objects, using harnesses instead of collars to prevent neck trauma, and keeping nails trimmed to appropriate lengths to prevent snags and tears are all practical measures. For dogs with severe vWD, avoiding activities with a high risk of impact injuries, such as agility courses with hard jumps or uncontrolled off-leash running in dense brush, may be advisable.

Dental care is an area that requires special attention in dogs with vWD. Regular dental cleanings under anesthesia carry hemorrhagic risk, so maintaining good oral hygiene through daily tooth brushing, dental chews, and regular veterinary dental assessments can help minimize the need for professional cleanings. When dental procedures are necessary, they should be planned with the same careful preparation as any surgical procedure in a vWD-affected dog.

Owners of dogs with vWD should maintain an emergency preparedness plan that includes knowing the location of the nearest emergency veterinary hospital with blood banking capabilities, having the dog's medical records and vWD test results readily accessible, and understanding the basic first-aid measures for controlling external bleeding. Keeping styptic powder or gel on hand for minor nail or skin bleeding is practical. Medical identification tags or collar attachments noting the dog's vWD status can be helpful in emergency situations.

Routine veterinary care including vaccinations, parasite prevention, and wellness examinations can proceed normally in dogs with vWD. However, intramuscular injections should be avoided when subcutaneous alternatives are available, and venipuncture sites should be held off with firm pressure for several minutes after blood draws to prevent hematoma formation.

Responsible breeding practices are the most effective tool for reducing the prevalence of Von Willebrand's Disease in affected breeds. Genetic testing before breeding is strongly recommended for all breeds in which vWD mutations have been identified and DNA tests are commercially available. The goal of a well-designed breeding program is not necessarily to eliminate all carriers from the gene pool immediately, as this could severely reduce genetic diversity in some breeds, but rather to ensure that no affected puppies are produced and to gradually reduce the carrier frequency over successive generations.

The recommended breeding strategy depends on the inheritance pattern of the specific type of vWD. For Type 1 vWD, where the inheritance involves incomplete dominance, the ideal mating is between two clear (homozygous normal) dogs. If a carrier dog possesses exceptional breed qualities that justify its inclusion in a breeding program, it may be bred to a clear dog, with the understanding that approximately 50 percent of the offspring will be carriers. All puppies from such breedings should be tested, and carrier offspring should only be placed in pet homes with spay/neuter agreements or bred exclusively to clear partners in future generations.

For Types 2 and 3 vWD, which follow autosomal recessive inheritance, the same principles apply with even greater emphasis on testing. Carrier-to-carrier matings must be strictly avoided, as they carry a 25 percent probability of producing affected puppies with severe bleeding disorders. Carrier-to-clear matings will produce no affected offspring but will produce approximately 50 percent carriers, who should be identified through testing and managed appropriately in future breeding decisions.

Breed clubs and registries play an important role in promoting genetic health by establishing testing requirements, maintaining open health databases, and educating breeders about the importance of vWD screening. Several breed clubs have implemented mandatory vWD testing for breeding stock, and some kennel clubs require proof of vWD testing for registration of litters in high-risk breeds. These institutional efforts complement individual breeder responsibility and have contributed to meaningful reductions in vWD prevalence in some breed populations.

Prospective puppy buyers should ask breeders for documentation of vWD testing on both the sire and dam before purchasing a puppy from an at-risk breed. Reputable breeders will readily provide test results and should be transparent about the vWD status of their breeding animals. Buyers should be cautious of breeders who dismiss the importance of vWD testing or claim that the condition is not a concern in their lines without providing genetic documentation.